Retraction: Human monoclonal antibody GNX-8 directed to extended type 1 chain: specific binding to human colorectal cancer

Abstract Background : Preclinical and clinical studies have demonstrated that immunotherapy has effectively delayed tumor progression, and the clinical outcomes of anti-PD-1/PD-L1 therapy were related to PD-L1 expression level in the tumors. A 131 I-labeled anti-PD-L1 monoclonal antibody tracer, 131 I-PD-L1-Mab, was developed to study the target ability of non-invasive Cerenkov luminescence imaging in colorectal cancer xenograft mice.Method: Anti-PD-L1 monoclonal antibody labeled with 131 I( 131 I-PD-L1-Mab), and in vitro binding assays were used to evaluate the affinity of 131 I-PD-L1-Mab to PD-L1 and their binding level to different colorectal cancer cells, and compared with flow cytometry, western blot analysis, and immunofluorescence staining. The clinical application value of 131 I-PD-L1-Mab was evaluated through biodistribution and Cerenkov luminescence imaging, and different tumor-bearing models expressing PD-L1 were evaluated.Results: 131 I-PD-L1-Mab showed high affinity to PD-L1, and the equilibrium dissociation constant was 1.069×10 -9 M. The competitive inhibition assay further confirmed the specific binding ability of 131 I-PD-L1-Mab. In four different tumor-bearing models with different PD-L1 expression, the biodistribution and Cerenkov luminescence imaging showed that the RKO tumors demonstrated the highest uptake of the tracer 131 I-PD-L1-Mab, with a maximum uptake of 1.613 ± 0.738% ID/g at 120 h.Conclusions: There is a great potential for 131 I-PD-L1-Mab noninvasive Cerenkov luminescence imaging to assess the status of tumor PD-L1 expression and select patients for anti-PD-L1 targeted therapy.

Download Full-text

Structure of a human monoclonal antibody Fab fragment against gp41 of human immunodeficiency virus type 1.

Proceedings of the National Academy of Sciences ◽

10.1073/pnas.89.15.7154 ◽

1992 ◽

Vol 89 (15) ◽

pp. 7154-7158 ◽

Cited By ~ 40

Author(s):

X. M. He ◽

F. Ruker ◽

E. Casale ◽

D. C. Carter

Keyword(s):

Monoclonal Antibody ◽

Human Immunodeficiency Virus ◽

Human Immunodeficiency Virus Type ◽

Virus Type ◽

Human Monoclonal Antibody ◽

Fab Fragment ◽

Immunodeficiency Virus

Download Full-text

Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management

Case Reports in Oncology ◽

10.1159/000480634 ◽

2017 ◽

Vol 10 (3) ◽

pp. 897-909 ◽

Cited By ~ 31

Author(s):

Jonathan Kapke ◽

Zachary Shaheen ◽

Deepak Kilari ◽

Paul Knudson ◽

Stuart Wong

Keyword(s):

Diabetes Mellitus ◽

Monoclonal Antibody ◽

Type 1 Diabetes ◽

Type 1 Diabetes Mellitus ◽

Immune Checkpoint ◽

Autoimmune Diabetes ◽

Human Monoclonal Antibody ◽

Programmed Death ◽

Autoimmune Diabetes Mellitus

With the introduction of immune checkpoint inhibitors into clinical practice, various autoimmune toxicities have been described. Antibodies targeting the receptor:ligand pairing of programmed death receptor-1 (PD-1) and its cognate ligand programmed death-ligand 1 (PD-L1) in rare reports have been associated with autoimmune diabetes mellitus. We report 2 cases of rapid-onset, insulin-dependent, type 1 diabetes mellitus in the setting of administration of nivolumab, a fully human monoclonal antibody to PD-1, and atezolizumab, a humanized monoclonal antibody to PD-L1. This appears to be the first report of autoimmune diabetes mellitus associated with atezolizumab. In addition, we provide a brief review of similar cases reported in the literature and a discussion of potential mechanisms for this phenomenon and propose a diagnostic and treatment algorithm.

Download Full-text

Abstract 1077: Bufalin inhibited cell proliferation and expression of insulin-like growth factor 2 and type 1 receptor in human colorectal cancer cells

10.1158/1538-7445.am2012-1077 ◽

2012 ◽

Author(s):

Yong Zhang ◽

Dian-Xu Feng ◽

Ronghua Zhao ◽

Chao Chen ◽

Jie Wang ◽

...

Keyword(s):

Colorectal Cancer ◽

Cell Proliferation ◽

Growth Factor ◽

Cancer Cells ◽

Insulin Like Growth Factor ◽

Human Colorectal Cancer ◽

Colorectal Cancer Cells ◽

Human Colorectal Cancer Cells

Download Full-text

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM-151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells

Annals of Oncology ◽

10.1093/annonc/mdx367.040 ◽

2017 ◽

Vol 28 ◽

pp. v135

Author(s):

S. Napolitano ◽

G. Martini ◽

E. Martinelli ◽

C.M. Della Corte ◽

V. Belli ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Human Colorectal Cancer ◽

Colorectal Cancer Cells ◽

Epidermal Growth ◽

Antibody Inhibition ◽

Human Colorectal Cancer Cells

Download Full-text

Teplizumab for Treatment of Type 1 Diabetes Mellitus

Annals of Pharmacotherapy ◽

10.1345/aph.1r065 ◽

2012 ◽

Vol 46 (10) ◽

pp. 1405-1412 ◽

Cited By ~ 3

Author(s):

Jessica W Skelley ◽

Lindsey K Elmore ◽

Jeffrey A Kyle

Keyword(s):

Diabetes Mellitus ◽

Monoclonal Antibody ◽

Type 1 Diabetes ◽

Type 1 Diabetes Mellitus ◽

Human Monoclonal Antibody ◽

Clinical Trial Data ◽

Data Sources ◽

Β Cells ◽

Phase 3

Objective: To review the pharmacology, pharmacokinetics, safety, and efficacy of teplizumab and evaluate relevant clinical trial data. Data Sources: Searches of MEDLINE, International Pharmaceutical Abstracts, ClinicalTrials.gov, American Diabetes Association scientific posters, and Google Scholar (1966-May 2012) were conducted using the key words teplizumab. anti-CD3 monoclonal antibody, MGA031, and hOKT3γ1 (Ala-Ala). Searches were limited to articles published in English. Study Selection and Data Extraction: Clinical trials evaluating teplizumab for type 1 diabetes mellitus (T1DM) published in English were selected from the data sources. All published relevant abstracts were included. References cited in identified articles were used for additional citations. Data Synthesis: T1DM accounts for up to 10% of all cases of diabetes mellitus, T1DM is characterized as a chronic and progressive autoimmune disease leading to the destruction of insulin-producing β-cells of the pancreas. Teplizumab is a humanized Fc-mutated anti-CD3 monoclonal antibody that alters the function of the T-lymphocytes that mediate the destruction of the insulin-producing β-cells. While clinical data are limited, both Phase 2 and Phase 3 studies have demonstrated preserved C-peptide response as a measure of insulin production, decreased exogenous insulin use, and improved grycemic control following a 12- to 14-day teplizumab infusion in patients diagnosed with T1DM within the previous 6 weeks. However, 1 Phase 3 trial tailed to find the same benefits in those diagnosed with T1DM within the previous 12 weeks when a lower cumulative teplizumab dose was used. Initial studies indicated that teplizumab is well tolerated, with a self-limiting rash as the most commonly reported adverse effect. Conclusions: Teplizumab is an anti-CD3 human monoclonal antibody with promising activity in treatment of patients with T1DM, Results from Phase 3 trials are needed to further determine safety, efficacy, and dosing frequency.

Download Full-text